The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Cisplatin-Associated Nephrotoxicity and Pathological Events
Abstract
Cisplatin (cis-diamminedichloroplatinum(II)) is an effective chemotherapeutic agent, and is successfully used in the treatment of a wide range of tumors. Despite its effectiveness as an anti-tumor drug, nephrotoxic side effects have significantly restricted its clinical use. Tubular epithelial cell deletion following cisplatin treatment is a major cause of renal injury. Oxidative stress significantly contributes to cisplatin-associated cytotoxicity, and use of antioxidants could counteract such cytotoxic effects of cisplatin. The renal microenvironmental changes following cisplatin treatment is a complex process and could be broadly categorized into three main pathological events, which at times might overlap: initial cytotoxic events, inflammatory events and fibroproliferative events. Stress responses and heat shock proteins generated following cisplatin treatment are actively involved in the initiation and progression of these events. In this article, we will briefly summarize factors involved in various phases of cisplatin-induced renal injuries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Fulda, S., Sieverts, H., Friesen, C., Herr, I., & Debatin, K. (1997) · PubMed · Cited by 443
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells
Lieberthal, W., Menza, S. A., & Levine, J. S. (1998) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1998.274.2.f315 · Cited by 377
Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis
Shiraishi, F., Curtis, L. M., Truong, L., Poss, K., Visner, G. A., Madsen, K., Nick, H. S., & Agarwal, A. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.278.5.f726 · Cited by 315
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure
Ramesh, G., & Reeves, W. B. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00101.2003 · Cited by 282
Megyesi, J., Safirstein, R. L., & Price, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1497 · Cited by 272
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., & Kaufmann, S. H. (1997) · Blood · doi:10.1182/blood.v90.3.935 · Cited by 269
Increase in metallothionein produced by chemicals that induce oxidative stress
Bauman, J. W., Liu, J., Liu, Y. P., & Klaassen, C. D. (1991) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(05)80017-1 · Cited by 239
Henkels, K. M., & Turchi, J. J. (1999) · PubMed · Cited by 238
Assessment of Cisplatin-Induced Nephrotoxicity by Microarray Technology
Huang, Q. (2001) · Toxicological Sciences · doi:10.1093/toxsci/63.2.196 · Cited by 218
Refractory potassium repletion. A consequence of magnesium deficiency
Whang, R. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.1.40 · Cited by 203
Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α
Ramesh, G., & Reeves, W. B. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00413.x · Cited by 196
Apoptosis induced by cisplatin nephrotoxic injury
Lau, A. H. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00687.x · Cited by 187
Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., & Tedeschi, M. (1997) · Annals of Oncology · doi:10.1023/a:1008211226339 · Cited by 178
Satoh, M., Kashihara, N., Fujimoto, S., Horike, H., Tokura, T., Namikoshi, T., Sasaki, T., & Makino, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047522 · Cited by 168
Nagata, K. (2003) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2003.09.020 · Cited by 134
van de Water, B., Nagelkerke, J. F., & Stevens, J. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13328 · Cited by 128
Tudor, G., Aguilera, A., Halverson, D. O., Laing, N., & Sausville, E. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400688 · Cited by 122
Role of the Increase in p21 in Cisplatin-Induced Acute Renal Failure in Rats
Miyaji, T., Kato, A., Yasuda, H., Fujigaki, Y., & Hishida, A. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v125900 · Cited by 119
Protection Effects of Taurine Supplementation against Cisplatin-Induced Nephrotoxicity in Rats
Saad, S. Y., & Al‐Rikabi, A. C. (2002) · Chemotherapy · doi:10.1159/000048587 · Cited by 112
Daugaard, G., Rossing, N. N., & R�rth, M. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257365 · Cited by 111
Hepatocyte Growth Factor Protects Renal Epithelial Cells from Apoptotic Cell Death
Liu, Y., Sun, A. M., & Dworkin, L. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8676 · Cited by 93
Razzaque, M. S., & Taguchi, T. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199709)183:1<24::aid-path1106>3.0.co;2-b · Cited by 87
Self-citationFerreira, C. G., Tolis, C., Span, S. W., Peters, G. J., van Lopik, T., Kümmer, A., Pinedo, H. M., & Giaccone, G. (2000) · PubMed · Cited by 83
Re, F. D., Böhm, S., Oriana, S., et al. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686237 · Cited by 82
Martinis, B. S. D., & Bianchi, M. D. L. P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0860 · Cited by 81
Kruidering, M., van de Water, B., Zhan, Y., Baelde, J. J., de Heer, E., Mulder, G. J., STEVENS, J., & Nagelkerke, J. F. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400392 · Cited by 80
Eichhorst, S. T., Müerköster, S. S., Weigand, M. A., & Krammer, P. H. (2001) · PubMed · Cited by 79
Razzaque, M. S., Kumatori, A., Harada, T., & Taguchi, T. (1998) · The Nephron journals/Nephron journals · doi:10.1159/000045217 · Cited by 78
Self-citationZhan, Y., van de Water, B., Wang, Y., & Stevens, J. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203060 · Cited by 76
Ms, R., & Taguchi, T. (1999) · PubMed · doi:10.14670/hh-14.1199 · Cited by 74
Self-citationMethylglyoxal Enhances Cisplatin-induced Cytotoxicity by Activating Protein Kinase Cδ
Godbout, J. P., Pesavento, J. J., Hartman, M. E., Manson, S. R., & Freund, G. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m100385200 · Cited by 71
Schaaf, G., Maas-Bakker, R. F., de Groene, E. M., & Fink‐Gremmels, J. (2002) · Free Radical Research · doi:10.1080/1071576021000005267 · Cited by 71
Acute and long-term nephrotoxicity of cis-platinum in man
Groth, S., Nielsen, H. J., S�rensen, J. B., Christensen, A. B., Pedersen, A. G., & R�rth, M. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00306754 · Cited by 69
The Control of Vascular Endothelial Cell Injury
Murota, S.-I., Morita, I., & Suda, N. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb42289.x · Cited by 65
Razzaque, M. S., Shimokawa, I., Nazneen, A., Higami, Y., & Taguchi, T. (1998) · Cell and Tissue Research · doi:10.1007/s004410051139 · Cited by 65
Self-citationBurstyn, J. N. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.21.4237 · Cited by 61
Razzaque, M. S., Koji, T., Kumatori, A., et al. (1999) · Histochemistry and Cell Biology · doi:10.1007/s004180050368 · Cited by 59
Self-citationRazzaque, M. S., Foster, C. S., & Ahmed, A. R. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0967 · Cited by 55
Self-citationYamate, J., Sato, K., Ide, M., Nakanishi, M., Kuwamura, M., Sakuma, S., & Nakatsuji, S. (2002) · Veterinary Pathology · doi:10.1354/vp.39-3-322 · Cited by 55
Prevention of Nephrotoxicity of Cisplatin by Repeated Oral Administration of Ebselen in Rats
Yoshida, M., Iizuka, K., Terada, A., et al. (2000) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.191.209 · Cited by 49
Weekly cisplatin ± glutathione in relapsed ovarian carcinoma
Colombo, N., BINI, S., Miceli, D. D., Bogliun, G., Marzorati, L., Cavaletti, G., Parmigiani, F., Venturino, P., Tedeschi, M., Frattola, L., et al. (1995) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1995.05020081.x · Cited by 44
Razzaque, M. S., Shimokawa, I., Nazneen, A., Liu, D., Naito, T., Higami, Y., & Taguchi, T. (1999) · The Histochemical Journal · doi:10.1023/a:1003578928487 · Cited by 40
Self-citationSatoh, K., Wakui, H., Komatsuda, A., Nakamoto, Y., MIURA, A. B., Itoh, H., & Tashima, Y. (1994) · Renal Failure · doi:10.3109/08860229409044872 · Cited by 33
Cytokines and Growth Factors Involved in Peritoneal Fibrosis of Peritoneal Dialysis Patients
Oh, K., & Margetts, P. J. (2005) · The International Journal of Artificial Organs · doi:10.1177/039139880502800208 · Cited by 24
Life-Long Caloric Restriction Suppresses Age-Associated Fas Expression in the Fischer 344 Rat Kidney
Razzaque, M. S., Shimokawa, I., Koji, T., Higami, Y., & Taguchi, T. (1999) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.1999.0104 · Cited by 23
Self-citationExpression of Osteopontin in Cisplatin-Induced Tubular Injury
Iguchi, S., Nishi, S., Ikegame, M., Hoshi, K., Yoshizawa, T., Kawashima, H., Arakawa, M., Ozawa, H., & Gejyo, F. (2004) · Nephron Experimental Nephrology · doi:10.1159/000078643 · Cited by 17
Cited by
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Dietrich, J., Han, R., Yang, Y., Mayer-Pröschel, M., & Noble, M. (2006) · Journal of Biology · doi:10.1186/jbiol50 · Cited by 500
Risk Prediction of Contrast-Induced Nephropathy
McCullough, P. A., Adam, A., Becker, C. R., Davidson, C., Lameire, N., Stacul, F., & Tumlin, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.022 · Cited by 457
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Drug-associated renal dysfunction and injury
Choudhury, D., & Ahmed, Z. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0076 · Cited by 345
Metadata
- Authors
- Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S.
- Venue
- Contributions to Nephrology
- Publisher
- KARGER
- Published
- 2005
- Volume
- 148
- Pages
- 107-121
- OpenAlex
- W2099252920
- Cited by
- 256
- References
- 53
- FWCI
- 58.07
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.